Abiraterone acetate is a targeted therapy for advanced prostate cancer, specifically castration-resistant prostate cancer (CRPC). It works by inhibiting the enzyme CYP17, which plays a key role in the production of androgens (male hormones). By lowering androgen levels, abiraterone slows cancer progression and improves survival rates.
While the brand-name version, marketed as Zytiga, has been a breakthrough, its high cost limited accessibility for many patients. This created an urgent need for generic manufacturers to step in and make the drug affordable.
Read more: https://www.specialitymedz.com..../product/abiraterone
ถูกใจ
แสดงความคิดเห็น
แชร์
